- Home
- SUI vs BBIO Comparison
SUI vs BBIO Comparison
Compare SUI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUI | BBIO |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 14.2B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUI | BBIO |
|---|---|---|
| Price | $127.98 | $70.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 25 |
| Target Price | ★ $141.21 | $86.33 |
| AVG Volume (30 Days) | 661.0K | ★ 2.3M |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 1426.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,306,100,000.00 | $502,076,000.00 |
| Revenue This Year | $5.24 | $89.45 |
| Revenue Next Year | $5.08 | $73.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $115.53 | $31.77 |
| 52 Week High | $137.85 | $84.94 |
Technical Indicators
Market Signals| Indicator | SUI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 43.46 |
| Support Level | $127.22 | $69.62 |
| Resistance Level | $130.21 | $78.96 |
| Average True Range (ATR) | 2.32 | 4.08 |
| MACD | -0.06 | -0.80 |
| Stochastic Oscillator | 49.51 | 13.89 |
Price Performance
Historical ComparisonAbout SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.